Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Pharmaceutical Technology

JULY 20, 2022

Researchers at Gladstone Institutes and UC San Francisco (UCSF) have discovered in a study that bromodomain and extraterminal (BET) proteins are vital for the body to fight Covid-19 infection. . The research also found that BET proteins play two distinct roles in affecting how the SARS-CoV-2 virus interacts with human cells. .

Protein 278

Protein Scientist Gene DNA 278

Pharmaceutical Technology

AUGUST 9, 2023

The proteins, which mimic those found in mother’s milk, target toxins released by harmful pathogens in the gut.

Protein 130

Protein Development 130

Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263

Protein Research Antibody Immune Response 263

BioSpace

NOVEMBER 28, 2023

In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.

Protein 122

Protein Development 122

Bio Pharma Dive

AUGUST 2, 2022

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

Protein 268

Protein Development Drugs 268

Drug Discovery World

APRIL 17, 2024

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. Under the license agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Protein 52

Protein Licensing Licensing Sales 52

Bio Pharma Dive

DECEMBER 16, 2022

The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

Protein 152

Protein Development Drugs 152

Bio Pharma Dive

DECEMBER 6, 2022

Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.

Protein 204

Protein Medicine Development 204

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins.

Protein 126

Protein Gene Bioassay DNA 126

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. OVs can be attenuated natural viruses or recombinant viruses.

Protein 130

Protein Gene Genetics Gene Therapy 130

XTalks

NOVEMBER 29, 2023

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105

Protein Production Marketing Development 105

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody 147

Antibody Development Protein 147

Drug Discovery World

APRIL 15, 2024

Roxana McCloskey , Senior Global Marketing Manager, Protein Therapeutics, SCIEX explores how innovative analytical approaches can help improve stability for cell line development. Cell line development (CLD) is a critical stage in the early production of biotherapeutic molecules.

Development 59

Development Protein Antibody Production 59

Bio Pharma Dive

MARCH 7, 2023

But biotech startups say there is still room to develop more. As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain.

Protein 360

Protein FDA Approval Drugs Development 360

Pharmaceutical Technology

MAY 9, 2023

Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Development 261

Development Sales Protein Production 261

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccination 231

Vaccination Vaccine Development Manufacturing 231

XTalks

JUNE 1, 2023

Univar Solutions , a leading global distributor of ingredients and chemicals, has recently been chosen to distribute ICL’s Rovitaris line of textured plant proteins in North America. The company prides itself on its relentless drive to continually develop and refine products that fill existing gaps in the market.

Protein 98

Protein Production Development Marketing 98

Drug Discovery World

FEBRUARY 14, 2024

Especially for rapidly-mutating viruses (such as SARS-CoV-2), tools that can help inform the rapid development of vaccines are crucial in being better prepared for future health crises. Unlike other types of vaccines that use viral genetic codes or viral vectors, recombinant protein vaccines use only the antigenic proteins themselves.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Protein 130

Protein Marketing Manufacturing Reagent 130

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 278

Drugs Protein Medicine Development 278

Drug Discovery World

JANUARY 22, 2024

A new infographic ‘ Four methods for thermal stability assessment of therapeutic proteins ‘ is now available to download for free. Thermal stability is among the most common critical quality attributes (CQAs) used for early developability assessment of biologics.

Protein 52

Protein Drugs Development 52

Drug Discovery World

FEBRUARY 13, 2024

It goes on to show that NX-2127, a potent targeted protein degrader with differentiated activity against BTK and IKZF1/3, can overcome this resistance across a broad range of acquired mutations. The post Protein degrader overcomes resistance in B-cell malignancies appeared first on Drug Discovery World (DDW).

Protein 52

Protein Medicine Scientist Research 52

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders. Nurr1 is a class of proteins important for the development and maintenance of dopamine in the brain.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

Protein 80

Protein Antibody Engineer Development 80

Scienmag

MAY 14, 2021

Approach opens a new avenue to study the biology of acute leukemia and for the development of new drugs Credit: Grembecka / Cierpicki Labs The protein made by the ASH1L gene plays a key role in the development of acute leukemia, along with other diseases.

Protein 70

Protein Development Research Gene 70

XTalks

APRIL 26, 2022

California-based startup Air Protein developed an alt meat called Air Meat, which is made using microbes that turn recycled carbon dioxide (CO2) into protein. So, how does the company make alt protein out of thin air? After that, in a process like beer fermentation, the protein is turned into a flour-like substance.

Protein 97

Protein Branding Production Scientist 97

Drug Discovery World

MARCH 5, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Antibody 59

Antibody Protein Vaccination Vaccine 59

Drug Discovery World

NOVEMBER 7, 2023

As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated.

Protein 52

Protein Development Drugs Research 52

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

Drug Discovery World

MAY 4, 2023

Adaptyv Bio, a Swiss/US technology company that develops infrastructure and tools for protein designers to engineer better proteins, has built a protein engineering foundry that it says will “pave the way” for protein designers to develop new medicines, novel enzymes and sustainable materials.

Engineer 52

Engineer Protein Life Science Medicine 52

Drug Discovery World

MAY 18, 2023

The development of a successful PROTAC candidate requires overcoming challenges at each stage of development. Read this guide to learn about common roadblocks, technologies to overcome them, and how to ensure you’re on the right track to building an efficient protein degrader.

Protein 52

Protein Development Drugs 52

Pharmaceutical Technology

MARCH 12, 2024

The US company is part of a burgeoning artificial intelligence (AI) market in early-stage drug development.

Protein 130

Protein Marketing Development Drugs 130